Who We Are
About ValeBorne
Building the definitive intelligence platform for genomic M&A due diligence.
Our Mission
Transform M&A Due Diligence from a Costly Bottleneck into a Strategic Advantage
Traditional M&A due diligence takes 4–8 weeks and costs hundreds of thousands of dollars. For biotech and AI drug discovery companies, the stakes are even higher—hidden technical risks, unverified IP claims, and operational gaps can destroy acquisition value.
ValeBorne was founded to change this. We combine AI-powered analysis with a proprietary 4-Pillar Framework to deliver comprehensive, actionable due diligence in days, not weeks. Every engagement builds our proprietary database, making each subsequent analysis faster and more accurate.
Our Model
A Platform Business Disguised as a Consultancy
ValeBorne is not a traditional consultancy. We are a platform business that starts with a service-led model to build the world's deepest proprietary database on genomic companies.
Every client engagement provides permission to incorporate anonymized insights into our database. Every analysis improves our AI models. Every credit issued strengthens our marketplace. This self-reinforcing network creates a defensible moat that grows stronger with each client.
The self-reinforcing loop
Client engagement
Each analysis adds anonymized, structured insights to the database.
Model improvement
Each dataset refines the AI engine's pattern recognition.
Faster, sharper analysis
Better models make the next engagement faster and more accurate.
Compounding moat
The network grows stronger with every client we serve.
Technology
The AI Engine Behind Our Analysis
Fine-tuned model
Our proprietary AI platform is built on a fine-tuned Qwen3.5-9B model trained on over 2,000 structured reasoning-chain examples covering 24+ companies across the biotech and AI drug discovery landscape.
Live RAG pipeline
A Retrieval-Augmented Generation pipeline connects to multiple data sources in real time: PubMed for scientific validation, USPTO and WIPO for patent verification, ClinicalTrials.gov for regulatory status, and proprietary data from our growing database of company analyses.
Purpose-built for DD
This is not a generic LLM. This is a purpose-built due diligence engine that understands the 4-Pillar Framework, cross-pillar correlations, and the specific risks that matter in biotech M&A.
Leadership
Meet the Team
ValeBorne was founded by four individuals with deep expertise across AI, finance, and biotechnology.
Mursal Elmi
[Placeholder] Mursal brings a decade of experience at the intersection of AI and business strategy. He has led product and go-to-market efforts for data-intensive platforms and sets ValeBorne's vision of due diligence as an intelligence product, not a service.
Obama Yusuf
[Placeholder] Obama is an AI/ML engineer with deep experience in model fine-tuning, retrieval systems, and production ML infrastructure. He architected ValeBorne's due diligence engine and its real-time RAG pipeline.
Anas Ali
[Placeholder] Anas has a scientific background spanning genomics and drug discovery. He leads pillar methodology development and ensures every technical claim in a ValeBorne report is grounded in peer-reviewed evidence.
Gabriel Algazali
[Placeholder] Gabriel's background is in finance and operations, with experience in valuation, capital structure analysis, and deal execution. He leads the Financial pillar methodology and ValeBorne's own operations.
Methodology
The ValeBorne 4-Pillar Framework
Our analysis is built on four interconnected pillars that provide a complete picture of acquisition risk:
Technical & Data Integrity
Assesses the reproducibility of scientific claims, platform robustness, data provenance, and technical debt. Uses peer-reviewed literature, code repository analysis, and independent validation.
Financial Health & Sustainability
Evaluates cash runway, revenue quality, burn rate, valuation, and capital structure. Uses funding history, SEC filings, and inference from comparable public companies.
Operational Risk & Scalability
Examines management team completeness, key person dependency, cultural health, and operational maturity. Uses LinkedIn analysis, Glassdoor sentiment, and team background verification.
Legal & Compliance
Reviews patent portfolios, freedom-to-operate, litigation history, regulatory compliance, and IP ownership clarity. Uses USPTO, PACER, and ClinicalTrials.gov data.
Cross-Pillar Correlation
What makes ValeBorne different is our ability to identify how risks across pillars compound. A management gap in clinical operations (Operational) combined with a weak patent portfolio (Legal) creates a much larger acquisition risk than either issue alone. Our analysis identifies and quantifies these compounding effects.
See the framework in action
Explore our three service tiers, or start a conversation about your next target.
View Solutions Get in Touch